Search the Newsreel

Corteva, Inc. (NYSE: CTVA) director acquires 412.9081 deferred stock units

Corteva, Inc. director Christopher J. Policinski acquired 412.9081 deferred stock units on July 31, 2026, as part of the Stock Accumulation and Deferred Compensation Plan for Directors. This transaction, based on a reference price of $78.71 per share, increased his total direct holdings to …

Stevanato Group SpA Revenue Breakdown – MUN:87N

Stevanato Group SpA (MUN:87N) reported a total revenue of €1.19 billion last year. The majority of this revenue, €997.60 million, came from its Biopharmaceutical and Diagnostic Solutions segment. EMEA was the largest contributing region, generating €663.30 million.

Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

Stevanato Group reported an 8% increase in revenue for the second quarter of fiscal 2026, reaching €302.0 million, primarily driven by its Biopharmaceutical and Diagnostic Solutions Segment. The company also updated its full-year 2026 guidance, expecting revenue between €1.260 billion and €1.280 billion, and …

Corteva (CTVA) director defers cash pay into stock units at $78.71

Corteva, Inc. director Janet Plaut Giesselman acquired 98.4627 stock units on July 31, 2026, by deferring cash compensation into common stock at a price of $78.71 per unit. Her direct holdings in the company now total 20,247.7383 stock units, including shares obtained through dividend …

Craftech Holdco acquired Balda C. Brewer, Inc. from Stevanato Group S.p.A..

Craftech Holdco successfully acquired Balda C. Brewer, Inc. from Stevanato Group S.p.A. on June 30, 2026. This transaction involved Stevanato Group S.p.A., which is listed on the NYSE under the ticker STVN. The news was published on August 4, 2026, at 5:23 pm EDT.

Stevanato Group (NYSE: STVN) grows H1 revenue, records disposal loss

Stevanato Group (NYSE: STVN) grows Q2 sales 8% and updates 2026 view

Stevanato Group (NYSE: STVN) announced an 8% increase in Q2 2026 sales, primarily driven by a 9% rise in its Biopharmaceutical and Diagnostic Solutions (BDS) segment and strong demand for High-Value Solutions (HVS), which grew 16%. The company also updated its full-year 2026 guidance, …

Stevanato Group (NYSE: STVN) grows Q2 revenue and sells Balda subsidiary

Stevanato Group (NYSE:STVN) Releases Earnings Results, Beats Expectations By $0.01 EPS

Stevanato Group (NYSE:STVN) Updates FY 2026 Earnings Guidance

Sage Park Acquires Balda C. Brewer, the California-based Contract Manufacturing Injection Molding Subsidiary From Stevanato Group S.p.A.

ANAHEIM, CA / ACCESS Newswire / August 4, 2026 / Craftech Holdco, a portfolio company of Sage Park, today announced the acquisition of Balda C. Brewer ("BCB"), the Ontario, California-based contract manufacturing subsidiary, from its parent company, Stevanato Group S.p.A ("Stevanato"). BCB is a …

Stevanato Group Q2 2026 Earnings Call: Complete Transcript

Stevanato Group reported an 8% year-over-year revenue growth in Q2 2026, reaching $302 million, driven by strong demand for injectable biologics and GLP-1 therapies. The company divested its California subsidiary, Balda C. Brewer, to focus on higher-value integrated drug delivery systems, a move expected …

ADM, Corteva Raise 2026 Profit Forecasts on Strong Processing and Seed Demand Outlooks

Archer-Daniels-Midland (ADM) and Corteva have both raised their 2026 profit forecasts due to strong oilseed processing outlooks and robust demand in key crop markets, particularly in the United States. ADM's revised forecast is attributed to increased farmer selling of corn and soybeans following a …

Stevanato Group (STVN) Q2 Earnings Top Estimates

Stevanato Group (STVN) reported Q2 earnings of $0.16 per share, surpassing the Zacks Consensus Estimate of $0.15, and revenues of $351.09 million, which slightly missed the consensus. The company has consistently beaten EPS estimates over the past four quarters and currently holds a Zacks …

Stevanato Group SpA earnings beat by €0.01, revenue topped estimates

Stevanato Group SpA (NYSE: STVN) reported strong second-quarter results, with EPS of €0.14 surpassing analyst estimates by €0.01 and revenue reaching €302M, exceeding the consensus estimate of €298.64M. The company's stock has seen a 14.20% increase in the last three months, despite a 10.83% …

The Manufacturers Life Insurance Company Sells 155,079 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

The Manufacturers Life Insurance Company reduced its stake in Teva Pharmaceutical Industries Ltd. by 30.8% in Q1 2026, selling 155,079 shares but still holding 348,898 shares valued at $10.5 million. Meanwhile, Teva insiders sold 270,493 shares worth approximately $9.48 million during the last quarter. …

Teva (TEVA) Is Up 8.8% After Raising 2026 Guidance And Highlighting Innovative Drug Momentum

Teva Pharmaceutical Industries saw its shares rise by 8.8% after it raised its 2026 revenue guidance to US$16.50–US$16.85 billion and affirmed mid-single digit revenue growth targets for 2027. The company's strategy focuses on a shift towards higher-value innovative medicines, driven by strong performance from …

A Look at Corteva Inc (CTVA) After 3.4% Decline -- GF Value $66.

Corteva Inc (CTVA) shares recently declined by 3.4%, bringing its price to $76.04. This price is 14.2% above its GF Value™ of $66.61, indicating the stock is "Modestly Overvalued" according to GuruFocus. Despite an above-average GF Score™ of 77/100, its P/E ratio is significantly …

Dear Teva Pharmaceutical Stock Fans, Mark Your Calendars for September 14

Teva Pharmaceutical Industries (TEVA) will replace its American Depository Shares with a direct listing of ordinary shares on the NYSE starting September 14, aiming to broaden its shareholder base and reduce capital costs. This strategic move could also lead to inclusion in major indices, …

UBS Group Issues Positive Forecast for Corteva (NYSE:CTVA) Stock Price

UBS Group has raised its price target for Corteva (NYSE:CTVA) from $86.00 to $89.00, while maintaining a "neutral" rating, indicating a potential 17.07% upside. This follows other positive analyst revisions from firms like Goldman Sachs and Deutsche Bank. Corteva also reported better-than-expected Q2 earnings, …

Teva Pharmaceutical (NYSE: TEVA) insider plans Rule 144 sale of 12,827 shares

An insider at Teva Pharmaceutical Industries Limited (NYSE: TEVA) has filed a Rule 144 notice to sell 12,827 ordinary shares, valued at approximately $447,350.60. The sale, expected around August 3, 2026, stems from a Restricted Share Unit Award that vested on August 1, 2024, …

Teva Pharmaceutical (NYSE: TEVA) holder plans $892K sale of ordinary shares

A holder of Teva Pharmaceutical Industries Limited (NYSE: TEVA) plans to sell 25,578 ordinary shares, valued at approximately $892,050.65, through Citigroup Global Markets, Inc. The sale is scheduled to occur on or after August 3, 2026, and relates to a Restricted Share Unit Award …

BMO raises Corteva stock price target to $100 on EBITDA outlook

BMO Capital has increased its price target for Corteva Inc. (NYSE:CTVA) to $100 from $95, maintaining an Outperform rating, due to an improved EBITDA outlook for 2027. The firm raised its 2027 EBITDA estimate to $4.5 billion, citing opportunities around an improved agricultural dynamic …

Investors brace for Stevanato earnings amid GLP-1 packaging surge By Investing.com

Stevanato Group SpA is set to report its second-quarter earnings, with analysts expecting significant year-over-year growth in EPS and revenue. Investors are keenly watching the company's ability to leverage the booming GLP-1 obesity drug market and the broader biologics expansion, focusing on its shift …

UBS Adjusts Price Target on Corteva to $89 From $86, Maintains Neutral Rating

UBS has adjusted its price target for Corteva (CTVA) to $89, up from $86, while maintaining a Neutral rating on the stock. This update reflects a change in the analyst's valuation, though the overall investment recommendation remains unchanged. The article also notes other recent …

Pacer Advisors Inc. Decreases Stake in Corteva, Inc. $CTVA

Pacer Advisors Inc. reduced its holdings in Corteva, Inc. (NYSE:CTVA) by 2.7% in the first quarter, selling 64,588 shares but still owning 2,289,146 shares valued at $191.62 million. Despite this, other institutional investors have recently increased their stakes in Corteva. The company announced a …

116,100 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Bought by Militia Capital Management LLC

Militia Capital Management LLC recently acquired 116,100 shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the first quarter, valued at approximately $3.5 million. This purchase is part of broader institutional investment activity, with hedge funds and other institutional investors collectively owning 54.05% of the …

Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Amundi

Amundi reduced its stake in Teva Pharmaceutical Industries Ltd. by 45.3% in the first quarter, selling over 1.46 million shares but still holding 1.77 million shares. Despite this, institutional ownership remains strong, with several major investors increasing their positions. Analysts maintain a "Moderate Buy" …

(STVN) Volatility Zones as Tactical Triggers

This article analyzes Stevanato Group S.p.a. (NASDAQ: STVN) using AI models to provide tactical trading triggers. It highlights a potential shift in near-term sentiment and offers three institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss zones. The analysis …

Why Teva Pharmaceutical Stock Surged This Week

Key Points Teva posted its Q2 results this week, reporting an earnings miss even though sales beat expectations. The company's forward guidance didn't deliver big surprises, but it looked solid enough. Investors were bullish on the company's announcement that it will be replacing its …

Corteva Raised Guidance and Still Dropped 12%. Is the Selloff Overdone?

Corteva, Inc. (CTVA) saw its stock drop nearly 12% despite beating earnings and raising its full-year outlook, primarily due to a revenue miss in its second quarter, particularly in Crop Protection. The market's anxiety also stems from the upcoming separation of the company into …

Stevanato Group (STVN) Could Be 19% Undervalued As Alina Pen Approvals Expand In Europe

Stevanato Group (STVN) is experiencing mixed share price momentum despite recent marketing authorizations for its Alina 30 and Alina 50 pen injectors in Europe. The company is considered 18.6% undervalued with a fair value of $24.39, driven by increasing demand for its drug delivery …

Corteva Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.25 Sh Revenue Breakdown – BMFBOVESPA:C1TV34 – TradingView

This article provides a revenue breakdown for Corteva Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.25 Sh (C1TV34) on the BMFBOVESPA. The main revenue contribution came from the United States, reporting 46.20 billion BRL last year, slightly up from 42.41 billion BRL the previous …

Janus Henderson Group PLC Has $145.08 Million Position in Teva Pharmaceutical Industries Ltd. $TEVA

Janus Henderson Group PLC increased its stake in Teva Pharmaceutical Industries Ltd. by 1.5% in Q1, holding 4.82 million shares valued at $145.08 million. Institutional investors collectively own 54.05% of Teva, and analysts maintain a "Moderate Buy" rating with an average price target of …

Corteva, Inc. $CTVA Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company reduced its stake in Corteva, Inc. (NYSE:CTVA) by 7.0% in the first quarter of 2026, selling 27,060 shares. Despite this, Corteva reported strong second-quarter adjusted EPS of $2.30, exceeding analyst estimates, and raised its fiscal 2026 EPS outlook. Analysts …

Axiom Investment Management LLC Takes $965,000 Position in Teva Pharmaceutical Industries Ltd. $TEVA

Axiom Investment Management LLC has acquired a new position of $965,000 in Teva Pharmaceutical Industries Ltd. during the first quarter, purchasing 32,032 shares. Institutional investors collectively own about 54.05% of the company, and analysts have a "Moderate Buy" consensus with an average target price …